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ABSTRACT
Background: Little is known about viral co-infections in African human immunodeﬁciency virus
(HIV)-infected children. We examined the prevalence of seromarkers for cytomegalovirus (CMV),
herpes simplex virus type 2 (HSV-2) and hepatitis B virus (HBV) infections among HIV-infected,
antiretroviral treatment (ART)-naı¨ve children in Lilongwe, Malawi.
Methods: Ninety-one serum samples were tested for IgG and IgM antibodies to CMV, and IgG
antibodies to HSV-2 and hepatitis B surface antigen (HBsAg). Baseline demographic, clinical and la-
boratory data were abstracted from electronic records.
Results: CMV IgG was the most common positive result in all age groups (in 73% of children
<1 year, and 100% in all other groups). Three patients were CMV IgM positive (3.3%), suggesting
acute infection. HSV-2 IgG was positive in four patients (4.4%), and HBsAg in two (2.2%).
Conclusions: CMV infection occurred early in life, and few children had speciﬁc signs of CMV in-
fection at the time of ART initiation. Unrecognized HBV infection represents opportunities for test-
ing and treatment of HIV/HBV co-infected children.
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BACKGROUND
Co-infections in people living with human immuno-
deficiency virus (HIV) activate the immune system
and drive progression of their HIV infection [1]. In
sub-Saharan Africa (SSA), HIV progression in chil-
dren is faster than in comparable groups of children
in Europe and the USA [2]. The causes for this phe-
nomenon are not fully understood, but more fre-
quent viral co-infections are likely to contribute [3].
However, few studies have reported seroprevalence
of common viral co-infections among HIV-infected
children in resource-limited settings. Specific
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research regarding cytomegalovirus (CMV) [3–5],
herpes simplex type 2 (HSV-2) [6] and hepatitis B
virus (HBV) [3, 7–10] in SSA are scarce, despite the
fact that the majority of children with HIV live there.
In Malawi, data on seroprevalence of these viruses
have been reported only in adults [11–13]. More re-
gional data about HIV and other virus co-infection is
urgently needed to better understand patients’ clin-
ical course and outcomes.
CMV acquisition is almost ubiquitous during in-
fancy in SSA; data from The Gambia showed that
approximately 85% of children were infected by 1
year of life [14]. In HIV-infected children, CMV ap-
pears to be even more common and 79% of children
were infected by 6 weeks of age in Zimbabwe [4].
Furthermore, CMV replicates more rapidly in the
presence of HIV, impacting neurodevelopment and
hearing function [5]. HSV-2 seroprevalence has
been reported to be three times higher among HIV-
infected adults than in the general population [15].
HSV-2 infection often presents with oral and ano-
genital ulcers but can also cause serious systemic
manifestations [16], particularly in neonates where
HSV-2 infection has a poor prognosis [17].
Data on paediatric HBV/HIV co-infection from
Malawi is lacking, but in adults it is common, with re-
ported prevalence between 16% and 20% [11–13].
HBV/HIV co-infection has been associated with im-
mune reconstitution syndrome following antiretro-
viral treatment (ART) initiation [18]. Hepatoxicity,
progression of HBV-related liver disease and HBV
drug resistance are other possible complications [18].
Furthermore, mother to child transmission of HIV
(MTCT) can be affected not only by maternal but
also by child co-infections including genital tract infec-
tion with HSV and systemic infections such as CMV
and HBV, and adversely impact MTCT rates [19].
We aimed to investigate the seroprevalence of
viral co-infections in a group of ART-naı¨ve, HIV-
infected Malawian children starting ART and relate
our findings to specific age groups to add to the
understanding of their epidemiology in this
population.
METHODS
From the 410 HIV-infected children aged between 3
months and <15 years that started ART between
May 2008 and December 2010 during the course of
the Trioped study [20], 275 (67%) baseline serum
samples were available. Epi Info 6 was used to deter-
mine study sample size using expected infection
prevalence, and samples from 91 patients were ran-
domly selected using Microsoft Excel Rand function.
Testing was performed at the University of North
Carolina (UNC) project laboratory. Demographic,
clinical and other baseline data were obtained from
electronic patient files. Levels of immunosuppression
were defined according to the World Health
Organization (WHO) definitions [21], anthropo-
metric measures were calculated according to the
WHO reference growth standards of 2007 using the
WHO Anthro Plus Software version 1.0.4 for chil-
dren 0–19 years old [22]. Severe wasting was
defined as a body mass index (BMI) for Age Z-score
< 3 standard deviation (SD), and stunted was
defined as a Height for Age Z-score < 2 SD, ac-
cording to the classification standards of the WHO
guidelines [23]. Age- and sex-specific reference
ranges were used for aspartate transaminase (AST)
and alanine transaminase (ALT) (Appendix 1).
All samples were screened for CMV IgG and
IgM. CMV IgG antibodies were tested with the Bio-
Rad Platelia CMV IgG enzyme-linked immunoab-
sorbent assay (ELISA) (Bio-Rad, Marnes-la-
Coquette, France). We compared the optical density
(OD) of the sample with the concentration in
Arbitrary Units per millilitre (AU/ml) of the calibra-
tors of the standard curve [OD¼ function (AU/
ml)] to interpret the results. For CMV IgM antibod-
ies, we used the Bio-Rad Platelia CMV IgM ELISA.
Sample Ratios [sample OD/cut-off value (CO)] of
1.10 were considered positive for IgM antibodies
to CMV. All samples were tested for HSV-2 antibod-
ies against the HSV-2 G2 protein using the Bio-Rad
Platelia HSV-2 IgG ELISA. Reactive samples with a
sample ratio (sample OD/CO) 1.10 were con-
sidered anti-HSV-2 positive. Hepatitis B surface anti-
gen (HBsAg) was examined with the Genetic
Systems
TM
HBsAg enzyme immunoassay 3.0 (Bio-
Rad, Redmond, USA) and samples with an OD
above the specific CO for each test run were con-
sidered to be HBsAg positive. Table 1 shows the in-
terpretation of positive test results for each viral
marker.
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The study was approved by National Health
Sciences Research Committee, Lilongwe, Malawi,
the Baylor College of Medicine institutional review
board, Houston, Texas, USA, and the Liverpool
School of Tropical Medicine Research Ethics
Committee, United Kingdom.
RESULTS
Of the 91 HIV-infected children, 46 (50.5%) were
female. The median age was 34 months, with a range
of 3–165 months [interquartile range (IQR): 63].
The age distribution of the study population was 15
children (16.4%) <12 months, 41 (45.1%) 1–4
years, 29 (31.9%) 5–9 years and 6 (6.6%) 10–14
years. Two-thirds of the children had advanced
WHO clinical stages 3 or 4 (Table 2). The mean ab-
solute CD4 of the total sample was 682 cells/mm3
(SD: 707.1) with a mean CD4 percent of 16% (SD:
9.2). Almost three in four children had advanced or
severe immunosuppression (Table 2). The median
viral load was 191,363 copies/mm3 (IQR: 27,678).
With regard to transaminases, the median AST was
41 U/l (IQR: 23) and the median ALT was 24.8 U/l
(IQR: 17). Of the children included in the study, 21
(23.1%) and 25 (27.5%) children presented with an
elevated level of AST and ALT, respectively
(Table 2). In relation to nutritional status, 71.4%
were stunted (65 of 91) and 9.9% (9) were severely
wasted (Table 2).
CMV IgG was positive in 87 children (95.6%,
95% CI: 88.6–98.3), CMV IgM in 3 (3.3%, 95% CI:
1.1–9.9), HSV-2 IgG in 4 (4.4%, 95% CI: 1.6–11.3)
Table 1. Interpretation of positive test results
CMV IgG Passive maternal transfer (if <12
months) or lifelong persistent infec-
tion (if 12 months)
CMV IgM Primary infection or reactivation
HSV-2 Passive maternal transfer (if <12
months) or lifelong persistent infec-
tion (if 12 months)
HBsAg Acute or chronic HBV infection
Table 2. Clinical and laboratory variables by age group
Variable <1 year 1 to <5 years 5 to <10 years 10 to <15
years
Total/overall
Viral Load median copies/mm3
(IQR)
332 917
(517 591)
254 769
(424 261)
102 480
(205 722)
76 873
(57 372)
191 363
(27 678)
Immunosuppression, n (%)
No 0 5 (12.2) 7 (24.1) 1 (16.7) 13 (14.3)
Mild 1 (6.7) 2 (4.9) 5 (17.3) 1 (16.7) 9 (9.9)
Advanced 1 (6.7) 2 (4.9) 7 (24.1) 1 (16.7) 11 (12.1)
Severe 11 (73.3) 30 (73.1) 9 (31) 3 (50) 53 (58.2)
No data 2 (13.3) 2 (4.9) 1 (3.5) 0 5 (5.5)
WHO clinical stage, n (%)
1 6 (40) 4 (9.7) 2 (6.9) 0 12 (13.2)
2 2 (13.3) 8 (19.5) 9 (31) 0 19 (20.9)
3 5 (33.4) 27 (65.9) 15 (51.7) 0 50 (54.9)
4 2 (13.3) 2 (4.9) 3 (10.4) 6 (100) 10 (11.0)
Elevated ALTa n (%) 0 12 (29.3) 10 (34.5) 3 (50) 25 (27.5)
Elevated ASTa n (%) 3 (20) 9 (22) 8 (27.6) 1 (16.7) 21 (23.1)
Nutritional statusb
Stunted n (%) 12 (80) 28 (68.3) 19 (65.5) 6 (100) 65 (71.4)
Severely wasted n (%) 3 (20) 4 (9.8) 0 2 (33.3) 9 (9.9)
Notes. aAge- and sex-speciﬁc AST and ALT reference ranges from the UNC laboratory were used (Appendix 1).
bSevere wasting was deﬁned as BMI for Age Z-score (BAZ) < 3 SD and stunted was deﬁned as a Height for Age Z-score < 2 SD.
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and HBsAg in 2 (2.2%, 95% CI: 0.5–8.5) (Table 3).
All children positive for CMV IgM, HSV-2 IgG and
HBsAg also had CMV IgG antibodies. No child had
more than two positive seromarkers. Only four chil-
dren (4.4%) were negative for all tests. Eleven
(73.3%) infants <1 year of age and all other children
were positive for CMV IgG (Table 3).
Only one child positive for CMV IgM had the
triad of fever, hepatomegaly and generalized lymph-
adenopathy (GL) at the time of ART initiation. This
patient also had a history of severe recurrent pneu-
monia leading to a WHO stage 3 classification. At
baseline, none of the children positive for CMV IgM
or CMV IgG antibodies had the diagnoses of colitis,
retinitis or encephalopathy, and no child infected
with HSV-2 had documented skin lesions, hepato-
megaly or GL. Among children with HBV infection,
one child presented with GL; none had jaundice or
hepatomegaly documented at ART initiation.
Liver transaminases (AST and ALT) were all
within age- and sex-specific normal ranges for the
children who were CMV IgM positive. One of the
patients who was HBsAg positive did have an ALT
that was 1.1 times the upper limit of normal.
DISCUSSION
Our study adds important local data about the sero-
prevalence of clinically relevant viral co-infections in
HIV-infected children in a geographical area where
evidence is scarce and variable. We found that all 76
children >1 year of age had serological evidence of
CMV infection, and 11 of the 15 infants <12
months were either CMV exposed or infected. Three
children had serological markers indicative of either
acute or reactivated CMV infection, but only one
had clinical features suggestive of CMV infection at
ART initiation (in the setting of limited capacity to
diagnose infections such as CMV retinitis or colitis
in Malawi). Fewer children had laboratory evidence
of HSV-2 or HBV infection (4.4 and 2.2%,
respectively).
CMV infection has been reported to be an early-
life event in Africa, promoted by HIV [4, 5] and our
findings support this, with all children infected by 1
year of age. The HSV-2 prevalence in our sample is
much lower than the 29.6% reported in a study from
Tanzania [6] but similar to findings in HIV-unin-
fected children in Germany where the prevalence
was <5% [24]. HBsAg positivity in HIV-infected
children in Africa varies widely, with studies report-
ing prevalence from 1.2% to 7.8% [3, 7–10]. The
seroprevalence of HBsAg in our study is similar to
studies in HIV-positive children in Ethiopia (2%),
the Democratic Republic of Congo (1.6%) or
Tanzania (1.2%) [7–9], but lower than in studies
from Kenya and Nigeria reporting 4% and 7.8%, re-
spectively [3, 10]. Different baseline conditions,
study design and selection bias are potential causes
of the differences in the seroprevalence of these viral
co-infections.
Routine HBV screening for all HIV-infected pa-
tients is recommended by the WHO [25], but has
not been implemented in Malawi or many SSA coun-
tries [7, 26]. It is particularly important in paediatrics
where an estimated 25% of children and infants co-in-
fected with HIV and HBV will develop cirrhosis and
carcinoma [27]. Evidence of previously unrecognized
acute or chronic HBV infection in HIV-infected chil-
dren (2.2% in this study) highlights a gap in the diag-
nosis of this co-infection in children. As of December
2014, the Malawian Ministry of Health reported
46,410 children (<15 years) were alive and on ART
[28]. Using the 2.2% (95% CI: 0.5–8.5) HBsAg posi-
tivity from this study, approximately 1016 (between
232 and 3945) Malawian children on ART may have
Table 3. Seropositivity for CMV, HSV-2 and HBsAg in HIV-infected children by age group
Age group Viral
marker
<1 year
n (%)
1 to <5 years
n (%)
5 to <10 years
n (%)
10 to <15 years
n (%)
Total n
(%, 95% CI)
CMV IgG n (%) 11 (73.3) 41 (100) 29 (100) 6 (100) 87 (95.6, 88.6–98.3)
CMV IgM n (%) 2 (13.3) 1 (2.4) 0 0 3 (3.3, 1.1–9.9)
HSV-2 IgG n (%) 0 2 (4.9) 2 (6.9) 0 4 (4.4, 1.6–11.3)
HBsAg n (%) 0 0 1 (3.4) 1 (16.7) 2 (2.2, 0.5–8.5)
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undiagnosed HBV co-infection. This is a substantial
number, and improvement in universal HBV screen-
ing in HIV-infected patients is needed. In addition,
implementation of universal maternal HBV screening
as part of routine antenatal care would allow for peri-
natal vaccination for prevention of vertical HBV
transmission.
With respect to HBV treatment, the standard na-
tional paediatric first-line ART regimens over the
period from 2004 to present has been zidovudine or
stavudine with lamivudine plus nevirapine or efavir-
enz, with WHO-recommended dosing [29, 30]. Of
these medications, only 3TC is effective against
HBV, and 3TC monotherapy for HBV is associated
with rapidly developing resistance [18]. Tenofovir is
another antiretroviral with activity against HBV and
became available for general use in Malawi for all
HIV-infected patients in 2013 [31]. Current national
guidelines allow for its use in children >35 kg and
>3 years of age [26], but the drug has been also
approved by the Food and Drug Administration for
children over 2 years and greater than 10 kg [32].
While more widespread use of tenofovir for treat-
ment of paediatric HIV may be limited owing to con-
cerns about renal and bone side effects, guideline
revisions should be considered to allow for situ-
ational use of this medication in younger, smaller
children with known HIV-HBV co-infection, who
could be identified in the future through expanded
standard screening programs.
LIMITATIONS
This study has a number of limitations. First, the
small sample size allows only a descriptive analysis.
The study was not powered to find associations be-
tween seroprevalence and other parameters; and the
cross-sectional design prevented us from analysing
risk factors. Secondly, no information about expos-
ure and likely transmission routes of viral co-
infections was available. Thirdly, serologic laboratory
tests have limitations in that passively transferred
maternal CMV or HSV-2 IgG antibodies can persist
in the child’s circulation up to the age of approxi-
mately 12 months and do not necessarily represent
infection in the child. Interpretation of negative anti-
body test results is difficult when tests are performed
before sufficient antibody is produced or when
antibody production is impaired. Furthermore, HSV-
2 IgG antibodies do not distinguish between active
and latent infection, and there is evidence that the
sensitivity and specificity of HSV-2 tests used in SSA
vary, and are generally lower than in studies from the
USA and Europe [33]. Finally, HBsAg measurement
underestimates the HBV prevalence as patients with
negative HBsAg can be HBV DNA positive [34].
CONCLUSIONS
CMV infection early in life was common in this co-
hort of HIV-infected children initiating ART, but of
unclear clinical significance. Acute or chronic HBV
infection was much less prevalent, but opportunities
for screening and treatment are currently being
missed. Policy and practice changes to improve out-
comes in HBV/HIV co-infected children are needed.
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APPENDIX
Transaminases levels of reference
Table A1. Normal levels of reference of ALT by age and sex at UNC-project laboratory (in U/l)
Alanine aminotransferase U/l 5–20 10 years to <18 years F
5–30 10 years to <18 years M
5–25 4 years to <10 years F
5–25 7 years to <10 years M
5–20 4 years to <7 years M
5–30 1 year to <4 years
13–45 1 day to <1 years
Table A2. Normal levels of reference of AST by age and sex at UNC-project laboratory (in U/l)
Aspartate aminotransferase U/l 15–45 12 years to <18 years
10–60 10 years to <12 years
15–40 7 years to <10 years
15–50 4 years to <7 years
20–60 1 year to <4 years
15–60 >30 days to <1 years
25–75 0 day to 30 days
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